Company intelligence / Profile preview

TransferAI

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

TransferAI is an artificial intelligence-driven biotechnology company focused on accelerating drug discovery through advanced transfer learning techniques. The company addresses the challenge of limited experimental data by utilizing pre-trained models to predict molecular properties and biological activities more accurately. Founded by the creator of the DeepChem open-source project, TransferAI provides a platform that enhances lead optimization and virtual screening processes. Their technology is designed to reduce the time and cost associated with bringing new small molecule therapeutics to the clinic.

Modalities: Small molecule
Industry: Drug Discovery Services

Beyond the preview

Go deeper on TransferAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TransferAI.

Explore the full profile